{
    "clinical_study": {
        "@rank": "120990", 
        "arm_group": [
            {
                "arm_group_label": "Epigallocatechin-3-gallate (EGCG)", 
                "arm_group_type": "Active Comparator", 
                "description": "EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "No active substance is given."
            }
        ], 
        "brief_summary": {
            "textblock": "Fragile X syndrome (FXS) present alterations in synaptic plasticity that produce\n      intellectual disability. can produce improvement. Estrogens (targeting Estrogen Receptors\n      beta (ER-\u03b2)can act as neuroprotective agents, promoting synaptic plasticity and neurite\n      outgrowth, and health benefits derived from flavonoids, as the flavonol epigallocatechin\n      gallate (EGCG), phytoestrogens of natural origin are partially explained by their\n      interaction with membrane ER. Selective ER-\u03b2 flavonoids are thus good candidates for their\n      therapeutic evaluation in intellectual disabilities. EGCG also targets central intracellular\n      transduction signals altered in FXS and improves memory recognition in a FXS animal\n      model(adenosine triphosphate (ATP)-inhibitor of phosphatidylinositol 3-kinase (PI3K)and\n      mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK1/2).\n      This study targets the synaptic plasticity alterations that underlie the learning and memory\n      impairment but also the computational disability in FXS. The hypothesis is that EGCG can act\n      by favoring the physiological processes involved in cognition."
        }, 
        "brief_title": "Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Fragile X Syndrome", 
        "condition_browse": {
            "mesh_term": "Fragile X Syndrome"
        }, 
        "detailed_description": {
            "textblock": "Rare diseases leading to intellectual disability, such as Fragile X syndrome (FXS), where\n      alterations in synaptic plasticity are involved, may benefit from treatments targeting\n      Estrogen Receptors beta (ER-\u03b2). Estrogens can act as neuroprotective agents, promoting\n      synaptic plasticity and neurite outgrowth, and health benefits derived from flavonoids, as\n      the flavonol epigallocatechin gallate (EGCG), phytoestrogens of natural origin are partially\n      explained by their interaction with membrane ER. Selective ER-\u03b2 flavonoids are thus good\n      candidates for their therapeutic evaluation in intellectual disabilities. EGCG also targets\n      central intracellular transduction signals (EGCG is an ATP-inhibitor of PI3K, and mTOR and\n      ERK1/2) altered in FXS and improves memory recognition in a FXS animal model. This study\n      targets the synaptic plasticity alterations that underlie the learning and memory impairment\n      but also the computational disability in FXS. The hypothesis is that EGCG can act by\n      favoring the physiological processes involved in cognition."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have been diagnosed of Fragile X syndrome (FXS), aged between 18-40 years, have given\n             the consent to participate (official custody).\n\n          -  To understand and accept experimental procedures and signing and informed consent\n             (parents and/or tutors)\n\n          -  Subjects with age comprised between 18 and 40 years\n\n          -  Use of contraceptive methods in female subjects\n\n          -  Regular menstrual cycle (26-32 days duration) in female subjects\n\n          -  Moderate mental disability (IQ>40)\n\n          -  Body mass index (BMI) comprised between 18.5 and 29.9 kg/m2, and body weight between\n             50 and 100 kg.\n\n          -  Non-smokers\n\n        Exclusion Criteria:\n\n          -  Subjects with neurological disease other than FXS, relevant medical disease,\n             co-morbid mental disorder or currently taking any treatment that could interfere with\n             cognitive function or alter any key biomarkers and biochemical parameters analyzed.\n\n          -  Having suffered from any major illness or undergoing major surgery in the last three\n             months before the study;\n\n          -  Regular ingestion of medication in the month preceding the study. Exceptions were\n             made for single doses of symptomatic medication administered up to the week preceding\n             the trial.\n\n          -  Current ingestion of vitamin supplements or catechins or non steroidal\n             antiinflammatory drug (NSAID) in the two weeks preceding the study.\n\n          -  History of gastrointestinal, hepatic or renal problems or any other cause that may\n             alter processes of absorption, distribution, metabolism, or excretion of the drug, or\n             that might suggest gastrointestinal irritation to drug.\n\n          -  Subjects following a vegetarian diet.\n\n          -  Practice of physical exercise for more than 2 hours per day or energy consumption of\n             more than 3000 kcal per week."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855971", 
            "org_study_id": "TESXF"
        }, 
        "intervention": [
            {
                "arm_group_label": "Epigallocatechin-3-gallate (EGCG)", 
                "description": "EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.", 
                "intervention_name": "Epigallocatechin-3-gallate (EGCG)", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Epigallocatechin-3-gallate (EGCG)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "No active treatment is given.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Matched placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estrogens", 
                "Epigallocatechin gallate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 19, 2013", 
        "location": {
            "contact": {
                "email": "rtorre@imim.es", 
                "last_name": "Rafael de la Torre, PharmD", 
                "phone": "0034933160484"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08003"
                }, 
                "name": "Parc de Salut MAR, Hospital del Mar Medical Research Institute-IMIM"
            }, 
            "investigator": [
                {
                    "last_name": "Rafael de la Torre, PharmD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Magi Farre, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF)", 
        "overall_contact": {
            "email": "rtorre@imim.es", 
            "last_name": "De la Torre Rafael, PharmD", 
            "phone": "0034933160484"
        }, 
        "overall_official": {
            "affiliation": "Parc de Salut Mar", 
            "last_name": "Rafael de la Torre, PhamD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Therapeutic response and treatment efficacy will be evaluated with Clinical Global Impressions-Improvement (CGI-I) scale.", 
            "measure": "Therapeutic response and treatment efficacy", 
            "safety_issue": "No", 
            "time_frame": "From baseline to 7 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855971"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Prepulse inhibition (PPI) of acoustic startle response", 
                "measure": "Neurophysiology", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Concentrations of PI3K/mTOR in human lymphocites.", 
                "measure": "Phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Concentration in plasma of oxidized- LDL.", 
                "measure": "Lipid Oxidation Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Bioimpedance body analysis composition", 
                "measure": "Body analysis composition", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Blood (clinical chemistry, hematology, coagulation) and urine analysis", 
                "measure": "Analytical chemistry", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Attention will be evaluated with CANTAB battery (Cambridge Cognition).", 
                "measure": "Attention", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Psychomotor Speed and Manual Skills will be evaluated with Motor Screening test (MOT) CANTAB.", 
                "measure": "Psychomotor Speed and Manual Skills", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Episodic Memory will be evaluated with CANTAB battery (Cambridge Cognition).", 
                "measure": "Episodic Memory", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Executive Functions will be evaluated with CANTAB battery (Cambridge Cognition).", 
                "measure": "Executive Functions", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Language will be evaluated with Boston Naming Test and with Token Test (TT).", 
                "measure": "Language", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Concentrations of Kinase 1(ERK) activity in human lymphocytes.", 
                "measure": "Extracellular signal-regulated kinase 1 (ERK) activity in human lymphocytes", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }, 
            {
                "description": "Quality of Life will be evaluated with Kidscreen-27.", 
                "measure": "Quality of Life Evaluation", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 7 months"
            }
        ], 
        "source": "Parc de Salut Mar", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Parc de Salut Mar", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}